SOLE Estrogen Substudy (SOLE-EST) - Investigating Changes in Estrogen Levels and Grip Strength for Patients Participating in the SOLE Trial
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Letrozole (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms SOLE-EST
- 15 Mar 2019 Planned End Date changed from 1 Dec 2020 to 1 Apr 2020.
- 15 Mar 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2020.
- 31 Aug 2018 Biomarkers information updated